Literature DB >> 19170681

Therapy of chemotherapy-induced peripheral neuropathy.

Thomas J Kaley1, Lisa M Deangelis.   

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is still a common and disabling side effect of many chemotherapy agents in use today. Unfortunately, neither prophylactic strategies nor symptomatic treatments have proven useful yet. This review will discuss the diagnosis and evaluation of neuropathy in cancer patients, as well as reviewing the various prophylactic and symptomatic treatments that have been proposed or tried. However, sufficient evidence is lacking to recommend any of these treatments to patients suffering with CIPN. Therefore, the best approach is to treat symptomatically, and to start with broad-spectrum analgesic medications such as non-steroidal anti-inflammatory drugs (NSAIDs). If NSAIDs fail, a reasonable second-line agent in properly selected patients may be an opioid. Unfortunately, even when effective in other types of neuropathic pain, anti-depressants and anticonvulsants have not yet proven effective for treating the symptoms of CIPN.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19170681     DOI: 10.1111/j.1365-2141.2008.07558.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  47 in total

Review 1.  Emerging trends in understanding chemotherapy-induced peripheral neuropathy.

Authors:  Jérémy Ferrier; Vanessa Pereira; Jérome Busserolles; Nicolas Authier; David Balayssac
Journal:  Curr Pain Headache Rep       Date:  2013-10

Review 2.  Inflammation: therapeutic targets for diabetic neuropathy.

Authors:  Jiyin Zhou; Shiwen Zhou
Journal:  Mol Neurobiol       Date:  2013-08-30       Impact factor: 5.590

Review 3.  Clinical effectiveness of low-level laser treatment on peripheral somatosensory neuropathy.

Authors:  Alireza Fallah; Alireza Mirzaei; Norbert Gutknecht; Amir Saberi Demneh
Journal:  Lasers Med Sci       Date:  2017-01-10       Impact factor: 3.161

4.  Amelioration of cisplatin-induced experimental peripheral neuropathy by a small molecule targeting p75 NTR.

Authors:  Amy Friesland; Zhiying Weng; Maria Duenas; Stephen M Massa; Frank M Longo; Qun Lu
Journal:  Neurotoxicology       Date:  2014-09-30       Impact factor: 4.294

5.  Antinociceptive effect of matrine on vincristine-induced neuropathic pain model in mice.

Authors:  Dun Linglu; Li Yuxiang; Xu Yaqiong; Zhou Ru; Ma Lin; Jin Shaoju; Du Juan; Sun Tao; Yu Jianqiang
Journal:  Neurol Sci       Date:  2013-12-14       Impact factor: 3.307

6.  Case report of a patient with chemotherapy-induced peripheral neuropathy treated with manual therapy (massage).

Authors:  Joan Elizabeth Cunningham; Teresa Kelechi; Katherine Sterba; Nikki Barthelemy; Paul Falkowski; Steve H Chin
Journal:  Support Care Cancer       Date:  2011-07-16       Impact factor: 3.603

7.  Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Efstathia Tzatha; Lisa M DeAngelis
Journal:  Oncology (Williston Park)       Date:  2016-03       Impact factor: 2.990

8.  Persistent hyperalgesia in the cisplatin-treated mouse as defined by threshold measures, the conditioned place preference paradigm, and changes in dorsal root ganglia activated transcription factor 3: the effects of gabapentin, ketorolac, and etanercept.

Authors:  Hue Jung Park; Jennifer A Stokes; Elaine Pirie; James Skahen; Yuri Shtaerman; Tony L Yaksh
Journal:  Anesth Analg       Date:  2012-12-07       Impact factor: 5.108

9.  Spinal astrocyte gap junctions contribute to oxaliplatin-induced mechanical hypersensitivity.

Authors:  Seo-Yeon Yoon; Caleb R Robinson; Haijun Zhang; Patrick M Dougherty
Journal:  J Pain       Date:  2013-02       Impact factor: 5.820

10.  Effect of histone deacetylase inhibitor JNJ-26481585 in pain.

Authors:  Kathryn E Capasso; Melissa T Manners; Rehman A Quershi; Yuzhen Tian; Ruby Gao; Huijuan Hu; James E Barrett; Ahmet Sacan; Seena K Ajit
Journal:  J Mol Neurosci       Date:  2014-08-02       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.